Literature DB >> 21908647

Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.

Giselle C Meléndez1, Jianping Li, Brittany A Law, Joseph S Janicki, Scott C Supowit, Scott P Levick.   

Abstract

AIMS: Substance P and neurokinin A (NKA) are sensory nerve neuropeptides encoded by the TAC1 gene. Substance P is a mast cell secretagogue and mast cells are known to play a role in adverse myocardial remodelling. Therefore, we wondered whether substance P and/or NKA modulates myocardial remodelling via a mast cell-mediated mechanism. METHODS AND
RESULTS: Volume overload was induced by aortocaval fistula in TAC1(-/-) mice and their respective wild types. Left ventricular internal diameter of wild-type (WT) fistulas increased by 31.9%; this was prevented in TAC1(-/-) mice (4.2%). Matrix metalloproteinase (MMP) activity was significantly increased in WT fistula mice and was prevented in TAC1(-/-) mice. Myocardial collagen volume fraction was decreased in WT fistula mice; this collagen degradation was not observed in the TAC1(-/-) group. There were no significant differences between any groups in tumour necrosis factor (TNF)-α or cell death. Cardiac mast cells were isolated from rat hearts and stimulated with substance P or NKA. We found that these cells degranulated only to substance P, via the neurokinin-1 receptor. To determine the effect of substance P on mast cells in vivo, volume overload was created in Sprague-Dawley rats treated with the NK-1 receptor antagonist L732138 (5 mg/kg/day) for a period of 3 days. L732138 prevented: (i) increases in cardiac mast cell density; (ii) increased myocardial TNF-α; and (iii) collagen degradation.
CONCLUSIONS: Our studies suggest that substance P may be important in mediating adverse myocardial remodelling secondary to volume overload by activating cardiac mast cells, leading to increased TNF-α and MMP activation with subsequent degradation of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21908647      PMCID: PMC3211974          DOI: 10.1093/cvr/cvr244

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  44 in total

1.  Mast cell heterogeneity: effects of neuroenteric peptides on histamine release.

Authors:  F Shanahan; J A Denburg; J Fox; J Bienenstock; D Befus
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

2.  Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload.

Authors:  G L Brower; J R Henegar; J S Janicki
Journal:  Am J Physiol       Date:  1996-11

3.  The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Authors:  Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

4.  Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells.

Authors:  Antonina Azzolina; Antonella Bongiovanni; Nadia Lampiasi
Journal:  Biochim Biophys Acta       Date:  2003-12-07

5.  Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.

Authors:  Mark S Kramer; Andrew Winokur; Jeffrey Kelsey; Sheldon H Preskorn; Anthony J Rothschild; Duane Snavely; Kalyan Ghosh; William A Ball; Scott A Reines; Dennis Munjack; Jeffrey T Apter; Lynn Cunningham; Mitchel Kling; Mohammed Bari; Albert Getson; Yih Lee
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

6.  A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.

Authors:  Tong J Gan; Christian C Apfel; Anthony Kovac; Beverly K Philip; Neil Singla; Harold Minkowitz; Ashraf S Habib; Jennifer Knighton; Alexandra D Carides; Hong Zhang; Kevin J Horgan; Judith K Evans; Francasca C Lawson
Journal:  Anesth Analg       Date:  2007-05       Impact factor: 5.108

Review 7.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

Authors:  Francis G Spinale
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

8.  Hemodynamic changes in rats after opening an arteriovenous fistula.

Authors:  M Huang; R L Hester; A C Guyton
Journal:  Am J Physiol       Date:  1992-03

9.  The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

Authors:  R de Wit; J Herrstedt; B Rapoport; A D Carides; J Guoguang-Ma; M Elmer; C Schmidt; J K Evans; K J Horgan
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

10.  Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart.

Authors:  Scott P Levick; David B Murray; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

View more
  27 in total

1.  Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT.

Authors:  Shaiban Jubair; Jianping Li; Heather M Dehlin; Edward J Manteufel; Paul H Goldspink; Scott P Levick; Joseph S Janicki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-12       Impact factor: 4.733

2.  Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue.

Authors:  Hao Wang; Jasmina Varagic; Sayaka Nagata; Neal D Kon; Sarfaraz Ahmad; Jessica L VonCannon; Kendra N Wright; Xuming Sun; Dwight Deal; Leanne Groban; Carlos M Ferrario
Journal:  J Surg Res       Date:  2020-04-30       Impact factor: 2.192

3.  Blocking substance P signaling reduces musculotendinous and dermal fibrosis and sensorimotor declines in a rat model of overuse injury.

Authors:  M F Barbe; B A Hilliard; P W Fisher; A R White; S P Delany; V J Iannarone; M Y Harris; M Amin; G E Cruz; S N Popoff
Journal:  Connect Tissue Res       Date:  2019-08-23       Impact factor: 3.417

Review 4.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

Review 5.  Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase.

Authors:  Joseph S Janicki; Francis G Spinale; Scott P Levick
Journal:  Pflugers Arch       Date:  2013-02-16       Impact factor: 3.657

6.  New frontiers in heart hypertrophy during pregnancy.

Authors:  Jingyuan Li; Soban Umar; Marjan Amjedi; Andrea Iorga; Salil Sharma; Rangarajan D Nadadur; Vera Regitz-Zagrosek; Mansoureh Eghbali
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

7.  Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling.

Authors:  Kirk R Hutchinson; Chandra Saripalli; Charles S Chung; Henk Granzier
Journal:  J Mol Cell Cardiol       Date:  2014-11-08       Impact factor: 5.000

Review 8.  Substance P in heart failure: the good and the bad.

Authors:  Heather M Dehlin; Scott P Levick
Journal:  Int J Cardiol       Date:  2013-11-12       Impact factor: 4.164

Review 9.  Mast cells in human and experimental cardiometabolic diseases.

Authors:  Guo-Ping Shi; Ilze Bot; Petri T Kovanen
Journal:  Nat Rev Cardiol       Date:  2015-08-11       Impact factor: 32.419

10.  Substance P acting via the neurokinin-1 receptor regulates adverse myocardial remodeling in a rat model of hypertension.

Authors:  Heather M Dehlin; Edward J Manteufel; Andrew L Monroe; Michael H Reimer; Scott P Levick
Journal:  Int J Cardiol       Date:  2013-07-29       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.